ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
44 announcements with these filters
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.
Akums Drugs and Pharmaceuticals scheduled a board meeting for August 8, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Akums Drugs and Pharmaceuticals' subsidiary will acquire Oriflame India's manufacturing business for ₹56 Crore. This deal expands Akums' manufacturing capacity in cosmetics and wellness products.
Akums Drugs and Pharmaceuticals Ltd filed its quarterly shareholding pattern, noting the removal of two entities from the promoter group due to their legal dissolution.
Akums Drugs and Pharmaceuticals concluded its 22nd AGM. Shareholders considered financial results, dividend declarations, and director re-appointments during the meeting.
The First Appellate Authority set aside a Rs.3.59 Crore penalty against Akums' subsidiary, Maxcure Nutravedics. This reversal follows an error in shipping addresses in 2025.
Akums reported a Rs.0.36 Crore penalty on its subsidiary, now set aside by an appellate authority. The company confirmed no financial impact from this regulatory matter.
Akums Drugs' subsidiaries received ₹22.27 Crore in income tax demands regarding historical expenditure disallowances. The company plans to appeal, citing the demands as legally unsustainable.
Akums reported FY26 revenue of ₹4,359 Cr (up 5.8%) and adjusted EBITDA of ₹522 Cr (up 13.3%). Strategy focuses on international CDMO expansion and margin improvement in API/Generic segments.
Akums Drugs received income tax assessment orders totaling ₹133.75 Crore for the 2018-2025 block period. The company plans to appeal these unsustainable demands.
Akums delivered a resilient FY26 with 5.8% revenue growth, navigating high raw material inflation and soft domestic demand through double-digit volume growth in its core CDMO segment.
Akums Drugs resumed 100% operations following a four-day disruption at Haridwar sites. The incident delayed ₹20 Crore in supply, but production loss recovery is expected.
Akums Drugs and Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The filing confirms adherence to SEBI listing and disclosure regulations.
Akums Drugs resumed over 70% of Haridwar operations following industry-wide labor unrest. Normalcy is being restored with local authorities after disruptions triggered by minimum wage reviews.
Akums Drugs and Pharmaceuticals appointed Mahajan & Aibara LLP as Internal Auditors for twelve months. The firm brings extensive multidisciplinary expertise to the company's internal control systems.